|
|
<< BACK TO AGENDA |
| PLENARY/WORKSHOP INFORMATION | |
|---|---|
| Title: | Plenary II: 'Aminoglycoside-induced Ototoxicity in Neonates ' |
| Speaker(s): |
Peter Steyger, PhD Associate Professor of Otolaryngology, Head & Neck Surgery, Oregon Health and Sciences University Peter Steyger’s severe (minus 85-100 dB) hearing loss originated with streptomycin treatment at 14 months during a bout of cerebral meningitis. With hearing aids he was able to decipher sounds and, after much speech training, to speak clearly. Following a mainstreamed English grammar school education, Peter entered university and embarked upon an academic research career that has led to his current research into the mechanisms of drug-induced deafness. In 2006, Peter received a cochlear implant which improved his auditory scene analysis tremendously, enhancing his social integration. He is currently Associate Professor of Otolaryngology at Oregon Health and Science University. |
| Abstract: | In neonatal intensive care units, aminoglycoside antibiotics are routinely administered to new admissions to control bacterial sepsis. Neonates that receive aminoglycosides for more than seven days, or concurrently receive mechanical ventilation for more than 4 days are far more likely to fail a new-born hearing screening test.
Hearing loss carries a socio-economic cost of over 1 million dollars (in year 2000$) over the life-time of each child with pre-lingual onset of hearing loss. Thus, there is considerable pressure to identify the mechanisms involved in form of drug-induced hearing loss, and ultimately to prevent. This presentation will discuss data from the neonatal clinic, and present hypotheses regarding the biological mechanisms involved in aminoglycoside ototoxicity.
Learning Objectives:
|
| Presentation(s): | Not Available |
| Handouts: | Not Available |